According to research report the contrast injector market is projected to reach USD 636.1 Million by 2021 from USD 445.5 Million in 2016, growing at a CAGR of 7.4% during the forecast period. The contrast injector market growth can primarily be attributed to factors such as the large number of approvals for contrast agents in different geographies and increasing number of public and private diagnostic centers. On the other hand, the side effects and allergic reactions associated with contrast agents are expected to limit the market growth to a certain extent. In the coming years, the contrast media injector market is expected to witness the highest growth rate in the Asia-Pacific region.

A number of key players are competing against each other in order to expand their existing customer base. In 2015, the contrast injector market was dominated by Bracco Imaging S.p.A (Italy), Bayer HealthCare (Germany), and Guerbet Group (France). Other players in this market include GE Healthcare (U.S.), Medtron AG (Germany), ulrich GmbH & Co. KG (Germany), AngioDynamics (U.S.) Sino Medical- Device Technology Co., Ltd. (China), Apollo RT Co., Ltd. (China), VIVID IMAGING (China), and Nemoto Kyorindo Co., Ltd. (Japan).

Bracco Imaging S.p.A is dominating the contrast injector market in 2016. The company is engaged in the discovery, development, manufacturing, and commercialization of imaging solutions for diagnostic imaging procedures to amplify the anatomic and functional visualization of internal body organs and areas. It also provides advanced administration systems for contrast imaging products. In 2011, the company acquired Swiss Medical Care (SMC) (Switzerland), to strengthen its automated system for contrast media injectors. Similarly, in 2008 and 2001, it acquired Acist Medical System (U.S.) and E-Z-EM Canada, Inc. (Canada) respectively. Bracco Imaging S.p.A serves customers in the Americas, Europe, and the Rest of the World with an employee base of 3,400 and a portfolio of 1,800 patients.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96046959

Bayer HealthCare is second largest player in the contrast injector market in 2016. The company deals in R&D activities along with the manufacturing and marketing of products. Bayer HealthCare has two reporting segments, namely, Pharmaceuticals and Consumer Health. The Pharmaceuticals segment deals in prescription products specifically for women’s health and cardiology and specialty therapeutics in the areas of oncology, hematology, and ophthalmology. The Consumer Health segment has three divisions: consumer care, medical care, and animal health. The medical care division comprises two business units— diabetes care and radiology. The radiology business unit offers contrast-enhanced diagnostic imaging equipment along with the necessary contrast agents.

Stakeholders of the Contrast Injectors Market

• Contrast Injector Manufacturers and Distributors
• Contrast Media/Contrast Agent Manufacturers and Distributors
• Companies Manufacturing X-ray, CT, MRI, and Cath Lab Equipment
• Niche Companies Manufacturing Novel Contrast Agents and Contrast Injectors
• Healthcare Institutions (Hospitals, Academic Medical Centers, and Outpatient Clinics)
• Radiology Centers
• Medical Imaging & Nuclear Medicine Consultants
• Health Insurance Players
• Research and Consulting Firms

Contact:

Mr. Shelly Singh

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

newsletter@marketsandmarkets.com